Company Analysis Ultragenyx Pharmaceutical Inc.
1. Summary
Advantages
- Price (38.69 $) is less than fair price (44.54 $)
- The stock's return over the last year (-17.36%) is higher than the sector average (-25.51%).
- Current debt level 2.9% is below 100% and has decreased over 5 years from 3.25%.
Disadvantages
- Dividends (0%) are below the sector average (0.5467%).
- The company's current efficiency (ROE=-220.26%) is lower than the sector average (ROE=9.01%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Ultragenyx Pharmaceutical Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.5% | -20.9% | -2% |
| 90 days | -11.6% | -25.3% | -12.1% |
| 1 year | -17.4% | -25.5% | 6.4% |
RARE vs Sector: Ultragenyx Pharmaceutical Inc. has outperformed the "Healthcare" sector by 8.14% over the past year.
RARE vs Market: Ultragenyx Pharmaceutical Inc. has significantly underperformed the market by -23.73% over the past year.
Stable price: RARE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RARE with weekly volatility of -0.3339% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (38.69 $) is lower than the fair price (44.54 $).
Price not significantly lower than the fair price: The current price (38.69 $) is slightly lower than the fair price by 15.1%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.09).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.45).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (12.68) is higher than that of the sector as a whole (4.61).
P/BV vs Market: The company's P/BV (12.68) is higher than that of the market as a whole (3.38).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (8.04) is lower than that of the sector as a whole (33.5).
P/S vs Market: The company's P/S indicator (8.04) is lower than that of the market as a whole (10.23).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-6.43) is higher than that of the sector as a whole (-19.46).
EV/Ebitda vs Market: The company's EV/Ebitda (-6.43) is lower than that of the market as a whole (15.44).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 45.02% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (45.02%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (38.84%).
5.4. ROE
ROE vs Sector: The company's ROE (-220.26%) is lower than that of the sector as a whole (9.01%).
ROE vs Market: The company's ROE (-220.26%) is lower than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (-40.69%) is lower than that of the sector as a whole (0.0151%).
ROA vs Market: The company's ROA (-40.69%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-46.96%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-46.96%) is lower than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5467%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
